VIRD.Y heads into its Q1 2026 results — due after market close on May 5 — carrying its best monthly price performance in recent memory and a short-selling picture that tells a more complicated story underneath.
The price momentum is the headline. The French geoscience and seismic-data group closed the week at $182.50, up 7.1% on the day and 6.8% on the week. The one-month gain is 20.9%. That's a meaningful re-rating in a sector — oil and gas equipment and services — that has spent much of the year under macro pressure. S&P upgraded Viridien's credit to "B" on April 8, and the company filed its 2025 Universal Registration Document earlier in the month. Both served as small but positive catalysts ahead of the earnings date.
The borrow market tells a more cautious story. Cost to borrow was running at 12.5% in the most recent available reading — well above the 1.5–2% range that characterised much of 2023 and early 2024, before a sharp reset upward began in the second half of that year. Availability and utilisation data are both stale as of the snapshot, so current lending-pool tightness is difficult to quantify precisely. What is clear is that borrowing is not cheap; a CTB in the low-to-mid teens represents a meaningful carry cost for anyone holding a short position into an earnings catalyst.
Short interest itself is more notable for its abrupt jump than its absolute level. Estimated shorted shares rose from 14 to 121 over a single session on April 24 — an 8x increase in reported short positions on the OTC-listed ADR. Context matters here: VIRD.Y is a lightly traded OTC depository receipt for the Paris-listed , and absolute share counts are tiny. The float-based percentage figure is unavailable in the data, which limits how aggressively this shift can be read. Days to cover, from the most recent FINRA fortnightly filing, stands at 1.59. That points to a position that is large enough to be worth watching but not yet at squeeze-risk territory.
The ORTEX short score is a modest 31, sitting near the low end of its recent range and implying that positioning looks cautious rather than aggressive. The score has hovered between 31 and 33 all month — there is no escalating short-side conviction building into the print. Factor scores add nuance: the EV/EBIT rank is in the 77th percentile, which on the fundamentals available — EV/EBITDA of 3.1x, EV/EBIT of 6.8x, revenues of approximately $1.17bn and EBITDA near $532m — suggests the market is not paying a premium multiple. The analyst recommendation differential ranks at the 88th percentile, meaning the stock's consensus skews notably more positive than the broader universe, even as 90-day EPS momentum is only in the 38th percentile.
Institutional ownership offers one further piece of context. Janus Henderson added 303,768 shares as of its March filing — the single largest reported change among top holders. BlackRock added 111,918 shares through March 31. UBS, conversely, trimmed its position by nearly 144,000 shares. The net institutional flow is not one-directional, but the presence of Janus and BlackRock building is a stabilising signal for a stock with a relatively thin register of 29 reported holders.
The next scheduled focus point is the Q1 results on May 5. The last earnings print in late February produced a modest one-day move of -0.7% and a five-day recovery of +1.4%, suggesting the market does not typically react violently to Viridien's numbers. Whether the strong April rally has pulled forward too much of the good news, or whether the S&P credit upgrade and improving cash-flow story (operating cash flow of $376m against capex of $251m) give bulls room to run, is the question the May 5 release will frame.
See the live data behind this article on ORTEX.
Open VIRD.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
